These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 31264439)
21. Vocal cord inflammatory myofibroblastic tumor with mucoid deposits harboring TIMP3-ALK fusion: A potential diagnostic pitfall. Yorita K; Togashi Y; Nakagawa H; Miyazaki K; Sakata S; Baba S; Takeuchi K; Hayashi Y; Murakami I; Kuroda N; Oda Y; Kohashi K; Yamada Y; Kiyozawa D; Michal M; Michal M Pathol Int; 2019 Jun; 69(6):366-371. PubMed ID: 31215130 [TBL] [Abstract][Full Text] [Related]
22. Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1. Haimes JD; Stewart CJR; Kudlow BA; Culver BP; Meng B; Koay E; Whitehouse A; Cope N; Lee JC; Ng T; McCluggage WG; Lee CH Am J Surg Pathol; 2017 Jun; 41(6):773-780. PubMed ID: 28490045 [TBL] [Abstract][Full Text] [Related]
23. Recurrent laryngeal inflammatory myofibroblastic tumor with positive anaplastic lymphoma kinase mimicking recurrent respiratory papillomatosis: a case report. He CY; Dong GH; Liu HG World J Surg Oncol; 2014 Mar; 12():54. PubMed ID: 24602144 [TBL] [Abstract][Full Text] [Related]
24. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767 [TBL] [Abstract][Full Text] [Related]
25. Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring Zhao T; Zhang X; Liu X; Ren M; Cheng Y; Wang J; Luo Z Front Oncol; 2023; 13():1147974. PubMed ID: 37035208 [TBL] [Abstract][Full Text] [Related]
26. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569 [TBL] [Abstract][Full Text] [Related]
27. FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor. Ouchi K; Miyachi M; Tsuma Y; Tsuchiya K; Iehara T; Konishi E; Yanagisawa A; Hosoi H Pediatr Blood Cancer; 2015 May; 62(5):909-11. PubMed ID: 25682942 [TBL] [Abstract][Full Text] [Related]
28. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors. Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033 [TBL] [Abstract][Full Text] [Related]
29. Advances in uterine inflammatory myofibroblastic tumours: Diagnostic challenges and risk stratification. Umetsu SE; Ladwig NR Histopathology; 2024 Aug; 85(2):215-223. PubMed ID: 38629322 [TBL] [Abstract][Full Text] [Related]
30. ALK Immunohistochemistry and Molecular Analysis in Uterine Inflammatory Myofibroblastic Tumor: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. Parra-Herran C Int J Gynecol Pathol; 2021 Jan; 40(1):28-31. PubMed ID: 33290353 [TBL] [Abstract][Full Text] [Related]
32. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259 [TBL] [Abstract][Full Text] [Related]
33. Epithelioid inflammatory myofibroblastic sarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature. Yu L; Liu J; Lao IW; Luo Z; Wang J Diagn Pathol; 2016 Jul; 11(1):67. PubMed ID: 27460384 [TBL] [Abstract][Full Text] [Related]
34. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125 [TBL] [Abstract][Full Text] [Related]
35. Inflammatory myofibroblastic tumor with predominant anaplastic lymphoma kinase-positive cells lacking a myofibroblastic phenotype. Hisaoka M; Shimajiri S; Matsuki Y; Meis-Kindblom JM; Kindblom LG; Li XQ; Wang J; Hashimoto H Pathol Int; 2003 Jun; 53(6):376-81. PubMed ID: 12787312 [TBL] [Abstract][Full Text] [Related]
36. Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma. Kubo T; Sugita S; Wada R; Kikuchi N; Iwasaki M; Ito Y; Sugawara T; Fujita H; Emori M; Tanaka R; Hirano H; Saito T; Hasegawa T Diagn Pathol; 2017 Mar; 12(1):26. PubMed ID: 28288693 [TBL] [Abstract][Full Text] [Related]
37. ALK-rearranged Inflammatory Myofibroblastic Tumor of the Placenta, With Observations on Site of Origin. Schoolmeester JK; Sukov WR Int J Gynecol Pathol; 2017 May; 36(3):228-229. PubMed ID: 27636888 [No Abstract] [Full Text] [Related]
38. ALK negative inflammatory myofibroblastic tumor of the orbit: a masquerading entity. Dutta V; Manoj MG; Malik A; Kumar P Indian J Ophthalmol; 2014 May; 62(5):627-9. PubMed ID: 24881614 [TBL] [Abstract][Full Text] [Related]
39. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300 [TBL] [Abstract][Full Text] [Related]